Deals
Pfizer Flexes Muscle With Priciest Purchase of Decade
Pfizer has been on the prowl for a major acquisition.
Photograph: Pfizer via AP PhotoThis article is for subscribers only.
Pfizer Inc. is proving that when it sees something it wants, it’s willing to pay up.
The company is buying injectable-medicine maker Hospira Inc. for about $17 billion, or $90 a share, a price that Hospira’s stock has never come close to on its own. In turn, Pfizer gains a steadily growing business to tack onto its established drugs unit that it has discussed spinning off.